Immusoft has presented data from its Phase I trial (NCT05682144) assessing ISP-001 nine months after administering a single low dose of 2.5 x 10⁷ cells/kg in a patient with mucopolysaccharidosis type I (MPS I). The data showed the patient—identified as a man in his mid-20s—to have pharmacodynamic, functional, reported quality of life, and daily living activity improvements, as well as reduced pain associated with MPS I.